Emicizumab
Hemlibra (emicizumab) is an antibody pharmaceutical. Emicizumab was first approved as Hemlibra on 2017-11-16. It is used to treat hemophilia a in the USA. It has been approved in Europe to treat hemophilia a. It is known to target coagulation factor IX and coagulation factor X.
| Trade Name | Hemlibra |
|---|---|
| Common Name | Emicizumab |
| Indication | hemophilia a |
| Drug Class | Monoclonal antibodies: humanized, cardiovascular indications |
